Abstract Type 1 diabetes is a chronic autoimmune disease resulting from T cell-mediated destruction of insulinproducing beta cells within pancreatic islets. Disease incidence has increased significantly in the last two decades, especially in young children. Type 1 diabetes is now predictable in humans with the measurement of serum islet autoantibodies directed against insulin and beta cell proteins. Knowledge regarding the presentation of insulin and islet antigens to T cells has increased dramatically over the last several years. Here, we review the trimolecular complex in diabetes, which consists of a major histocompatibility molecule,self-peptide, and T cell receptor, with a focus on insulin peptide presentation to T cells. With this increased understanding of how antigens are presented to T cells comes the hope for improved therapies for type 1 diabetes prevention.
Introduction
Type 1 diabetes (T1D), the immune-mediated form of diabetes, results from the specific T cell-mediated destruction of pancreatic islet beta cells [1••] . The major genetic determinant of T1D resides within the human leukocyte antigen (HLA) complex [2] . HLA genes explain more than 50 % of the genetic risk for disease development [3, 4] . Prior to the onset of clinical disease, which is marked by the presence of hyperglycemia, antibodies directed against insulin and proteins within insulin-producing beta cells are detectable in the serum. These islet autoantibodies make T1D predictable as the presence of two or more autoantibodies directed against insulin, glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), and zinc transporter 8 (ZnT8) results in a nearly 100 % progression to clinical T1D given enough time [5••] . Despite T1D being a predictable disease, it is not yet preventable. Antigenspecific therapies, especially with insulin preparations, have been utilized to induce tolerance and prevent clinical T1D onset with limited success [6] . Understanding how islet antigens are presented by HLA molecules to activate T cells is vital for improving antigen-specific therapies. We discuss in detail how insulin and other islet antigens are presented by diabetes at-risk HLA molecules to T cells. Utilizing this knowledge, we review the use of these novel peptides as therapies in preclinical studies using animal models of spontaneous autoimmune diabetes.
Trimolecular Complex
T cell activation by an antigen requires three components termed an immunologic synapse or trimolecular complex depicted in Fig. 1 [7, 8] . A major histocompatibility complex (MHC) class II molecule binds a peptide and this peptide/ MHC complex is presented on the cell surface of an antigenpresenting cell (dendritic cells, B cells, and macrophages) to interact with a T cell receptor expressed on a CD4 T cell. This occurs normally in adaptive immunity to bacterial and viral antigens. However, in the case of autoimmunity a self-peptide is presented by MHC II to a self or autoreactive T cell.
Major Histocompatibility Complex Class II Molecule
The majority of genetic risk for T1D development is conferred by genes in the HLA complex, which is divided into three regions termed class I, II, and III. Class II genes (termed DQ, DR, and DP) encode MHC class II proteins which are strongly associated with T1D risk. DQ and DR alleles are in close linkage disequilibrium on chromosome 6. Certain haplotypes (alleles on the same chromosome) are predominant in T1D. For example, approximately 90 % of all T1D patients have DR3/DQ2 and/or DR4/DQ8 haplotypes. The DQ8 (DQA1*0301, DQB1*0302) allele is present in 50-60 % of T1D patients and has the highest odds ratio for T1D development in genome-wide association studies with odds ratios ranging from 6.5 to 11 [3, 9] . Interestingly, the polymorphic DQ6 allele (DQB1*0602) provides dominant protection from diabetes development with an odds ratio as low as 0.03 [3, 9] . Understanding the protective role of DQ6 and other T1D resistance mechanisms is an active area of research.
MHC class II molecules are formed from two alpha and two beta chains. The α1 and β1 chains form the peptide binding groove, while the α2 and β2 anchor the MHC II molecule to the cell membrane. These molecules function to present processed antigens as peptides to CD4 T cells. As DQ8 is strongly implicated in T1D pathogenesis, we will focus on the structural characteristics of this molecule. DQ8 has been crystallized with both an insulin peptide and gliadin peptide in the peptide binding groove [10, 11] . Typically nine amino acids of a peptide fill the binding groove. The peptide binding groove of DQ8 anchors a peptide by binding amino acid side chains in 4 distinct pockets, pockets 1, 4, 6, and 9. Polymorphisms in the DQ α1 and β1 chains shape these pockets. A specific polymorphism in the DQ beta chain at position 57 changes an aspartic acid to valine, leucine, or alanine at pocket 9. Aspartic acid has a negatively charged side chain and this amino acid changes results in the loss of a salt bridge with a conserved arginine residue (positively charged side chain) at position 76 of the DQ8 alpha chain. Because of this, DQ8 favors peptides that have an acidic or negatively charged amino acid side chain (glutamic or aspartic acid) at position 9 [12] . Of note, the diabetes protective DQ6 molecule maintains aspartic acid at β57, allowing for the presentation of a much different peptide repertoire than DQ8. Taken together, subtle structural changes in the binding groove of MHC class II molecules may lead to diabetes by allowing presentation of certain self-peptides, decreasing the affinity by which self-peptides are presented or changing the position of peptide binding.
Self-Peptides
The second component of the trimolecular complex is a peptide or, in the case of autoimmunity, an autoantigen. A number of autoantigens have been described in T1D with almost all of them focused on proteins within beta cells. We will focus primarily on proinsulin/insulin as an autoantigen and several others in the section on posttranslational modification of islet autoantigens.
Insulin as an Autoantigen
Insulin is a major self-antigen for both T and B cells. Insulin autoantibodies are present in up to 90 % of young children that develop islet autoimmunity and eventually T1D [13, 14] . In addition, Pugliese and colleagues showed polymorphisms upstream of the insulin gene, variable number of tandem repeats (VNTR), are associated with levels of insulin expression in the thymus and T1D development risk [15] . It is hypothesized that the amount of insulin message present in the thymus (more VNTR) corresponds to regulation of autoreactive T cells and thus decreased T1D development; less insulin message potentiates the escape of autoreactive T cells from the thymus into peripheral circulation and enhances T1D risk.
Much of our knowledge regarding (pro) insulin peptide presentation in T1D comes from the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes [16] . Identical to humans, MHC class II molecules are necessary for disease development with murine IA g7 structurally similar to human DQ8 and DQ2 (both having polymorphisms at β57 resulting in the loss of aspartic acid) [17] [18] [19] . A critical amino acid sequence in the B chain of insulin, amino acids 9- Fig. 1 The trimolecular complex is consists of the following: (1) major histocompatibility complex class II molecule, (2) peptide, and (3) T cell receptor on a CD4 T cell. The MHC is composed of a binding groove with pockets that can accommodate amino acid side chains (represented as arrows) of the peptide. This interaction with distinct structural pockets (pockets 1, 4, 6, and 9) anchors the peptide to the MHC class II molecule. The amino acid side chains of the peptide not binding to the MHC molecule can interact with a T cell receptor, thereby activating a T cell. P1-P9 denote pockets in the peptide binding groove. MHC major histocompatibility complex 23 (B:9-23), is necessary for T1D development in the NOD mouse. Mutating the insulin gene such that a single amino acid is changed, B16 tyrosine to alanine, abrogates all diabetes development, and mice remain normoglycemic [20, 21] . This striking finding indicates that insulin B:9-23 is pathogenic and the amino acid mutation either leads to: (1) the peptide being unable to bind the murine MHC class II molecule or (2) insulin-specific T cell receptors cannot be activated without B16 tyrosine. Recent investigations suggest the latter to be the case. These studies reveal that B:9-23 can bind in multiple positions or Bregisters^in the IA g7 peptide binding groove. As depicted below in Fig. 2 , each register creates a new distinct epitope for T cell recognition even though the peptide is B:9-23 in each case.
Using register trapping techniques, Kappler and colleagues have determined that insulin B:9-23 binds in the unexpected, low affinity, register 3 to murine IA g7 [22] . Register 3 is low affinity as B22 arginine would occupy pocket 9, which is a very poor match as arginine has a positively charged side chain and pocket 9 is positively charged (from the polymorphism at β57). By creating a B:9-23 mimotope, B22 Arg→ Glu, binding to register 3 is now favored and this mimotope is able to stimulate T cells approximately 100-fold better than native B:9-23. Of importance, fluorescent IA g7 tetramers made with this mimotope detect CD4 T cells in the pancreas and pancreatic lymph nodes of prediabetic NOD mice, suggesting that B:9-23 presented at register 3 is an epitope for autoreactive T cells targeting pancreatic beta cells [23] .
We have recently translated these findings to humans, showing distinct patterns of cytokine response to the insulin B chain mimotope in subjects with and without T1D correlated to HLA-DQ genotype. Substituting a glutamic acid for arginine at position B22 of the insulin B:9-23 peptide resulted in robust inflammatory (IFN-γ) responses from new-onset T1D patients more than the native peptide. Unexpectedly, controls without diabetes not only responded with an IFN-γ response to the mimotope but also had strong production of IL10, especially if a non-risk DQ allele was present [24••] . IL10 has anti-inflammatory properties and is associated with regulatory T cells. Most models of autoimmunity indicate that there is a balance of inflammatory and regulatory immune responses. Our data in healthy controls suggests that this balance prevents T1D development.
Others groups have also documented a protective immune response to insulin and islet antigens in healthy controls. Peakman and colleagues identified epitopes in proinsulin and IA-2 that induce protective IL10 responses in healthy subjects [25] . Recently, Roep and coworkers found protective responses to a modified version of insulin B:30-C:13 that induced inflammatory responses in DQ8-positive T1D subjects and IL10 in some healthy controls [26] . CD4 T cell reactivity to various (pro) insulin epitopes in humans have also been identified from islet-infiltrating T cells [27••] , within pancreatic lymph nodes, [28] and in the peripheral blood [29] [30] [31] . Insulin-specific T cell responses are not just from CD4 T cells, as it is known that insulin B:10-18 activates CD8 T cells from T1D patients [32] .
Posttranslational Modification of Islet Autoantigens
Recent investigations into antigen processing and presentation have discovered that self-antigens may undergo posttranslational modification (PTM) to provide more immunogenic epitopes to activate autoreactive T cells. We will review three PTMs described in autoimmune disorders and examine their roles in T1D: (1) disulfide bond formation, (2) deamidation by tissue transglutaminase, and (3) citrullination by peptidyl arginine deiminase (PAD).
Disulfide bond formation can change the conformation and structure of a protein. Disulfide bonds or bridges are covalent bonds that form between free sulfhydryl (-SH) groups, which are found on the amino acid side chain of cysteine. The first described PTM in T1D comes from an internal disulfide bond within an insulin A-chain peptide, amino acids 1-13 [33] . T cell clones were identified from a child at risk for T1D (presence of insulin autoantibodies) using this peptide but not healthy controls. The cysteine residues at positions A6 and A 7 w e r e c r i t i c a l f o r T c e l l c l o n e r e c o g n i t i o n (GIVEQCCTSICSL). Interestingly, the vicinal disulfide bond did not alter binding to HLA-DR4 but instead activated specific T cell receptors.
A very well-studied PTM occurs in celiac disease (gluten sensitivity) in which tissue transglutaminase acts on gluten and gliadin proteins to form highly immunoreactive epitopes for CD4 T cells [34, 35] . Tissue transglutaminase converts glutamine (Gln) residues to glutamic acid (Glu). These modified peptides have increased MHC class II binding affinity as glutamic acid has a negatively charged side chain which is capable of anchoring peptides to pocket 1 or 9 of DQ8 and DQ2. The DQ2 and DQ8 alleles are present in almost all individuals with celiac disease with approximately 90 % of all patients having a DQ2 allele [36] . Of note, about 10 % of all T1D patients have celiac disease as both diseases share at risk DQ alleles [37] . In T1D, a number of islet peptides have been shown to increase binding affinity to DQ8 and T cell reactivity following conversion of Gln to Glu. Notably, the insulin B:30-C:13 peptide becomes more immunogenic with conversion of both Gln residues to Glu by inducing inflammatory T cell responses in T1D patients [26] . Similarly, there have been epitopes identified within GAD65 that also detect T cells at higher frequencies when Gln is converted to Glu [38] . Chromogranin A is also a target for autoreactive T cells in both murine and human diabetes. In the NOD mouse, isletinfiltrating T cells respond to the WE14 peptide presented by the mouse IA g7 in an unusual manner in which the peptide binds in only half the peptide binding groove [39] . It is hypothesized that tissue transglutaminase may act on the peptide to increase immunogenicity [40] . In fact, tissue transglutaminase treated WE14 stimulates T cells from newonset T1D patients to a greater degree than native or untreated peptides [41] .
A final well-studied PTM is the conversion of arginine to citrulline by the PAD enzyme in rheumatoid arthritis [42] . The conversion of arginine to citrulline results in the positively charged arginine side chain becoming neutral, allowing for higher affinity MHC class II binding or forming an epitope for specific T cell receptor activation. PAD is activated with inflammation and creates both citrillunated antibodies (anti-CCP antibodies) [43] and epitopes of vimentin and aggrecan capable of activating T cells when presented by specific MHC class II molecules [44] . In T1D, the conversion of arginine to citrulline within GAD65 creates epitopes that detect autoreactive CD4 T cells at higher frequencies in T1D patients compared to controls [38] .
T cell Receptor
The final component of the trimolecular complex is the T cell receptor (TCR). The TCR is composed of alpha and beta chains that interact with a peptide/MHC complex. The alpha and beta chains have both variable (V) and constant regions. Recombination allows for great diversity in TCR sequences such that millions of unique sequences are possible. TCR interaction with peptide/MHC occurs through the binding of complementary determining regions (CDR), three for each alpha and beta chain. It is believed that the germlineencoded CDR1 and CDR2 regions predominantly interact with α helices of the MHC, while CDR3 regions contact the bound peptide [45] . Compared to insulin peptides and MHC molecules, relatively little is known about TCR usage and diversity of autoantigen specific T cells. Again, much of our knowledge stems from the NOD mouse model of spontaneous autoimmune diabetes [46] . In the NOD mouse, about 70 % of TCRs responding to insulin B:9-23 presented by IA g7 use a conserved alpha chain component, termed TRAV5D-4 [47] . Interestingly, alpha chains containing TRAV5D-4 pair with many separate beta chains to recognize B:9-23, and are sufficient to induce insulin autoantibodies and diabetes [47] [48] [49] .
In humans, the ortholog to murine TRAV5D-4 is TRAV13-1. Interestingly, this human alpha chain can induce diabetes in the NOD model when combined with different mouse B:9-23-reactive CDR3 regions [47] . To study human insulin specific TCR usage, we used the insulin B:9-23 mimotope, described in the section on insulin as an autoantigen, to induce proliferation of peripheral blood T cells in three HLA-matched T1D patients all having the DQ8/DR4 and DQ2/DR3 haplotypes [24••] . CD4 T cells were sequenced for TCR alpha chains before and after proliferation. To monitor proliferation, peripheral blood mononuclear cells were labeled with a dye, carboxyfluorescein succinimidyl ester (CFSE), and cells dilute the dye as they divide; the CD4 + CFSE lo cells were then sorted and sequenced for TCR alpha chains. As depicted in Fig. 3a , several V alpha genes (TRAV and TRDV) are used by T cells more and less predominantly compared to baseline in all three subjects when stimulated with the insulin B:9-23 mimotope. Analyzing phylogenetic trees of V gene sequences indicates that four of the prevalent V genes (TRAV 38-1, TRAV 38-2, TRAV 19, and TRDV 1) cluster together based upon similarity in CDR1 and CDR2 sequences (Fig. 3b, c) . Interestingly, the CDR3 sequences vary in these clustered alpha chains. The V alpha gene skewing and clustering of dominantly used genes based upon CDR1 and CDR2 regions with variable CDR3 sequences is consistent with antigen-specific T cell proliferation and very similar to the findings from the NOD mouse.
In humans, the vast majority of our understanding regarding islet antigen-specific TCR usage comes from the study of T cells in the peripheral blood. However, the pancreatic islets are the target organ in T1D and sequencing TCRs from human islet infiltrating cells is crucial to understand disease pathogenesis. Both the retroperitoneal location and exocrine function of the pancreas make it difficult to obtain tissue for analysis. To address this problem, the Network for Pancreatic Organ Donors with Diabetes (nPOD) has been established to obtain pancreata and other organs (lymph nodes, spleen, and blood) from cadaveric organ donors with T1D and those who are autoantibody positive but without clinical disease [50] . This invaluable network is making the study of human islet infiltrating cells possible with a focus on TCR usage of the islet infiltrating T cells. Notably, an initial study analyzing the TCR repertoire from nPOD obtained pancreas tissue from a T1D patient having the HLA-DR4/DQ8 haplotype shows preferential usage of TRAV13-1 [51] .
Antigen Specific Therapy
The use of islet antigens or peptides to induce protective immunity, also called tolerance, is a major focus in the field. Antigen specific therapy is safe and holds the promise to induce regulatory T cells at the site of inflammation. Antigen therapy has been attempted at different stages of the disease process: at high genetic risk, islet autoimmunity, and newonset T1D, unfortunately with minimal success [52] . The most well-studied antigen for therapeutic intervention is insulin having been administered by oral, intranasal, subcutaneous with adjuvant, and intradermal routes [53, 54] . In the Diabetes Prevention Trial-Type 1 (DPT-1), a randomized doubleblinded placebo controlled trial was conducted in which atrisk T1D patients (n=372) were treated with oral insulin or placebo [55] . Unfortunately, the primary endpoint of delaying progression to clinic T1D was not achieved; however, a post hoc analysis revealed that participants with high levels of insulin autoantibodies had a delay in disease development of about 5 years [56] . The delay was even longer, 10 years, for those with the highest insulin autoantibody levels. A followup oral insulin trial through the National Institutes of Healthsponsored Type 1 Diabetes TrialNet is currently enrolling participants with high insulin autoantibody levels in an attempt to delay T1D progression (NCT00419562) [57] . Recently, the results of a small pilot trial using high-dose oral insulin in children at high genetic risk for T1D demonstrated safety and the induction of protective immunity to insulin [58] .
While oral insulin is being evaluated to potentially delay T1D onset, our recently gained insights into the molecular presentation of insulin B:9-23 to T cells allows for improved antigen-specific therapies. The insulin B:9-23 mimotope is a strong T cell agonist and has the potential to induce regulatory T cells in preclinical animal studies. Von Boehmer and colleagues used the insulin mimotope to induce tolerance in NOD mice by administering the peptide at a constant low dose through intraperitoneal osmotic pumps [59] . Naïve T cells were converted to Foxp3+ regulatory T cells and NOD diabetes was completely prevented both early and late in the disease course. This was not the case with identical low doses of the native B:9-23 peptide. The mimotope was unable to reverse NOD diabetes after hyperglycemia onset as monotherapy. This study indicates the potential of using a strong T cell agonist to improve the efficacy of antigen specific therapy for T1D intervention.
Conclusions
Type 1 diabetes is predictable and it naturally follows that the disease will be prevented. To date, major prevention efforts using insulin preparations (oral, intranasal, and subcutaneous) have had limited success. Understanding the molecular interactions of islet antigens with MHC and T cell receptors holds promise for improved antigen-specific therapies and biomarkers for disease progression. The register of insulin B:9-23 peptide presentation in murine and human T1D is critical for T cell activation. Utilizing this knowledge for therapeutic intervention may provide greater efficacy and biomarkers for monitoring therapeutic response. We believe tailoring immune therapy to a specific HLA molecule, autoantigen, and register of islet antigen presentation to autoreactive T cells represents precision medicine that will ultimately allow for T1D prevention.
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